
Caffeine is one of the most widely consumed stimulants worldwide and is commonly used to improve alertness and reduce fatigue. While its stimulating properties are well known, its potential influence on obsessive-compulsive symptoms has received comparatively little attention. Although caffeine has been associated with anxiety and heightened arousal, limited clinical evidence exists regarding its role in exacerbating compulsive behaviours. Understanding lifestyle factors such as caffeine consumption may therefore be important in evaluating symptom severity in individuals with obsessive-compulsive tendencies. We report the case of a 27-year-old woman with a long-standing history of compulsive nail-biting behaviour who presented with worsening symptoms during a period of increased caffeine intake. The patient had no other psychiatric comorbidities and was not receiving pharmacological treatment. During this period, she reported consuming three to four cups of coffee daily. Her obsessive-compulsive symptoms were assessed using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), which showed a score of 22, corresponding to moderate severity. Following the discontinuation of caffeine from her routine, the patient experienced a noticeable improvement in symptoms. Repeat assessment demonstrated a reduction in the Y-BOCS score to 8, indicating mild severity. The patient also reported feeling calmer, less restless, and better able to resist compulsive nail-biting urges. This case highlights caffeine as a potentially significant and modifiable trigger for the exacerbation of obsessive-compulsive symptoms in susceptible individuals. The marked improvement following caffeine cessation suggests that lifestyle factors may meaningfully influence symptom severity. Clinicians should consider evaluating caffeine intake during psychiatric assessments and counselling patients about potential behavioural triggers. Further research is required to better understand the relationship between caffeine consumption and obsessive-compulsive symptomatology.
Corticosteroids have been used for decades to treat various musculoskeletal conditions. A wide array of side effects, both local and systemic, which may be immediate or delayed in onset, has been reported. Soft-tissue calcifications following musculoskeletal corticosteroid injections represent delayed-onset local side effects. We report a case of soft-tissue swelling at the base of the right thumb in a 4.5-year-old girl, presenting as a hard lump approximately 16 months after treatment of paediatric trigger thumb with a local triamcinolone injection. The radiographs demonstrated ‘fluffy’ calcification in the soft tissue. Given the clear temporal association, absence of trauma and supporting literature, triamcinolone acetonide is the most likely etiological factor. To the best of our knowledge, such cases of paediatric trigger thumb have not been widely reported.
Polypharmacy is a growing concern in elderly populations due to rising multimorbidity and increased life expectancy. While medications are essential for managing chronic conditions, the cumulative burden of drugs can lead to adverse drug events, functional decline and poor quality of life. Deprescribing is the planned and supervised process of dose reduction or discontinuation of unnecessary or harmful medications offering a rational, patient-centred approach to optimise pharmacotherapy in older adults. This review explores the concept of deprescribing, its clinical rationale and various tools and frameworks such as screening tool of older persons’ potentially inappropriate prescriptions/screening tool to alert doctors to right treatment criteria, Beers Criteria, the Garfinkel algorithm and the Bruyère 5step model. Evidence from randomised controlled trials and meta-analyses demonstrates that deprescribing interventions can safely reduce medication burden without compromising clinical outcomes. Key challenges include clinician hesitation, patient resistance and systemic barriers such as lack of electronic health integration and standardised guidelines, especially in low and middle income countries like India. The review highlights the unique barriers and opportunities in the Indian context and emphasises the vital role of healthcare providers especially pharmacologists, pharmacists and physicians in promoting safe deprescribing practices. With the integration of digital tools, multidisciplinary collaboration and education reform, deprescribing can evolve from a theoretical concept to a practical standard of care in geriatric medicine.
Objectives: Neuropathic pain is a chronic disorder detrimental to the quality of life. In patients on cancer chemotherapy, involvement of peripheral nerves commonly leads to algesia. Gabapentin is a standard treatment for neuropathic pain. Donepezil, a cholinesterase inhibitor exerts neuroprotective effects and is useful in neurodegenerative diseases. Present study aimed to determine whether donepezil alone or in combination with gabapentin enhances anti-nociceptive and neuroprotective effect on chemotherapeutically induced peripheral neuropathic pain. Materials and Methods: Thirty female Wistar rats were divided into five groups comprising six each. The control group was treated with saline and group 2 with oxaliplatin (active control). Oxaliplatin 4 mg/kg twice weekly intraperitoneally was used to induce neuropathic pain for 28 days in all groups other than the control. Group 3, 4, and 5 received gabapentin 60 mg/kg, donepezil 1.5 mg/kg orally, and a combination of gabapentin 25 mg/kg and donepezil 1.5 mg/kg, respectively. Neuropathic pain assessment was followed by estimation of oxidative stress markers and interleukin-6 from the harvested sciatic nerve sample. Results: A combination of donepezil with gabapentin had demonstrated superior analgesic effects, corroborated by histopathological findings and alterations in oxidative stress markers. Conclusion: Donepezil gabapentin combination may be more effective in preventing the oxaliplatin-induced neuropathy clinically, along with having a neuroprotective effect.
Phenytoin (PHT), an anti-seizure medication for generalised and focal seizures, has non-linear pharmacokinetics and a narrow therapeutic window, increasing the risk of drug interactions, toxicity and adverse effects. We report a case of an 18-year-old male patient with a known case of seizure disorder of ataxia after concomitant administration of both PHT and valproic acid. Plasma PHT level was found to be supratherapeutic at 27.06 mcg/dL. PHT was discontinued with close monitoring of patient. Our report highlights PHT toxicity resulting from interaction between PHT and valproic acid even at standard therapeutic doses. To prevent drug-related adverse events, precise dosing and routine monitoring of PHT levels are essential, especially during dosage modifications, changes in formulation or the addition of new medication. Impact of avoidable adverse drug reactions on quality of life and economic burden can be reduced through preventive integrative approaches such as personalised medicine and therapeutic drug monitoring.